Clobenzorex
Clobenzorex is a central nervous system stimulant and anorectic drug, chemically classified as an N-substituted amphetamine and a phenethylamine. Marketed by Aventis under the trade name Asenlix in India, Mexico, Honduras, and other parts of Latin America.
A prodrug of amphetamine, clobenzorex is metabolized within hours of ingestion into 4-hydroxyclobenzorex and, in smaller amounts, amphetamine.
Chemistry
Synthesis
Condensation between amphetamine and 2-chlorobenzaldehyde gives a Schiff-base, . Subsequent reduction with sodium borohydride completed the synthesis of clobenzorex.Urinalysis
Clobenzorex can be detected by urine drug screening. It is one of many drugs that can cause a positive result for amphetamine in urine drug screening. It may be differentiated from use of amphetamine itself through testing for metabolites such as 4-hydroxyclobenzorex or enantiomeric analysis.Legal Status
Brazil
In Brazil, clobenzorex is a Brazilian [Controlled Drugs and Substances Act|controlled prohibited psychotropic].Canada
In Canada, clobenzorex is not specifically listed per the Controlled Drugs and Substances Act.Mexico
In Mexico, clobenzorex is available for sale over the counter at many Mexican pharmacies under the primary brand Asenlix, as well as generic trade names like Dinintel, Finedal, Rexigen, Itravil, all of which are available via prescription in India, and OTC in Mexico and Honduras, typically used as an appetite suppressant.United Kingdom
In the United Kingdom, clobenzorex is a Drugs controlled by [the UK Misuse of Drugs Act|controlled drug].United States
Clobenzorex is not controlled under the Controlled Substances Act of 1970 nor is it controlled under the Federal Analogue Act, as it is a derivative of benzphetamine. It is not subject to import controls and is legal to import and possess for personal medical use, provided all of the following conditions are met:- It is used to treat a condition with no FDA-approved medications or an orphan drug does not effectively treat a condition, and the risks of use have not been determined to outweigh to benefits of treatment;
- is not being deceptively and unlawfully marketed; and
- is part of an ongoing medical treatment plan that began in a foreign country.